{"id":4075,"date":"2020-08-26T09:18:22","date_gmt":"2020-08-26T09:18:22","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/ngs-panel-molecular-test-for-colon-cancer\/"},"modified":"2021-01-08T11:27:39","modified_gmt":"2021-01-08T11:27:39","slug":"ngs-panel-molecular-test-for-colon-cancer","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/ngs-panel-molecular-test-for-colon-cancer\/","title":{"rendered":"NGS panel molecular test for colon cancer"},"content":{"rendered":"
EKF subsidiary, Selah Genomics\u2019 newly introduced PrecisionPath next generation sequencing (NGS) technology cancer test is the first commercially available NGS panel molecular test priced under US$1,000 (\u20ac880). Recently launched in partnership with Greenville Health systems (GHS), the test paves the way for accessible, low-cost personalized medicine in colon cancer. PrecisionPath can help oncologists select the most effective treatment options for a patient based on the specific molecular profile of their tumour.
\n
\nSupplier:<\/strong> EKF Diagnostics
\nWebsite:<\/strong> <\/a><\/p>\n